SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vion (formerly Oncorx) interesting play on Gene Therapy
An SI Board Since April 1996
Posts SubjectMarks Bans Symbol
370 14 0 VION
Emcee:  Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
245Research Gift During the first quarter of 2001, the Company provided aJim Oravetz-5/14/2001
244NEW HAVEN — Vion Pharmaceuticals saw its first quarter losses increase as the coJim Oravetz-5/2/2001
243Vion Pharma 1Q Loss 14c/Share Dow Jones Newswires Vion Pharmaceuticals Inc. - NJim Oravetz-5/2/2001
242Lehman Brothers Health Care Conference presentation. March 1, 2001 vionpharm.coJim Oravetz-4/18/2001
241Wonder if they're hoping for a general market recovery 1st, they don't nScott H. Davis-4/6/2001
240[VION filed] "<i>to offer 5 million shares of common stock ... estimaDave-4/4/2001
239Vion Pharma Files 5M-Shr Shelf Registration Dow Jones Newswires WASHINGTON -- VJim Oravetz-4/4/2001
238From local paper:CuraGen, Vion show research at convention NEW HAVEN — Two of tJim Oravetz-3/30/2001
237Vion Says Phase I Trials Show Triapine Well Tolerated Dow Jones Newswires NEW HJim Oravetz-3/29/2001
236Thanks for the update, Jim. I hope Kessman can indeed find additional funding, bDave-3/27/2001
235Replay of CC available till 3/30. About 40 min or so long. Very positive outloJim Oravetz-3/26/2001
234Vion Pharmaceuticals Announces Status of Option Agreement for Vion-EPTTCO CancerJim Oravetz-3/20/2001
233Vion Pharm: AstraZeneca Won't Exercise Second Option Dow Jones Newswires NEJim Oravetz-3/20/2001
232Dave, beyond the statments I have already made there is not much else for me to Jim Oravetz-3/14/2001
231Re: <i>In three years time, it will be almost certain that the products thDave-3/14/2001
230Vion today announced that U.S. Patent No. 6,190,657 was issued from the U.S. PatJim Oravetz-2/26/2001
229Mr. Kessman concluded, "With several notable milestones reached, we begin tDave-2/22/2001
228NEW HAVEN, FEB 20 - VION today announced that it will proceed with a Phase I humJim Oravetz-2/21/2001
227Commenting on the company's 2000 results, Alan Kessman, president and chiefJim Oravetz-2/21/2001
226The Phase I clinical trial of VNP40101M sounds like good news. So why is VION stDave-2/20/2001
225Vion Pharma To Proceed With Anticancer Pdt Phase I Trial Dow Jones Newswires NEJim Oravetz-2/20/2001
224Jim, do you ever speak with mgmt at Vion? Any ongoing funding insight on Vion - Jim Oravetz-1/31/2001
223And another option is if the science is solid, has significant market value, if Scott H. Davis-1/27/2001
222In three years time, it will be almost certain that the products that are in PhaJim Oravetz-1/22/2001
221I would like to invest in VION long-term, but I'm concerned about their shorDave-1/22/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News